Serial quantification of BCR-ABL1 mRNA levels is a sensitive and specific measure of
response to therapy in patients with chronic myeloid leukemia and is used to define time …

Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic
indicator for patients with chronic myeloid leukemia, but historically, there has been …

Molecular monitoring of BCR-ABL1 transcripts for patients with chronic myeloid leukemia
(CML) is now used to assess response to tyrosine kinase inhibitors (TKIs), including …

For patients with chronic myeloid leukemia (CML), measurement of molecular response (ie
the level of BCR–ABL1 transcripts) is firmly established as a key element of disease …

The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients
treated with imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable …

With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …

Background: The evolution of BCR-ABL1 tyrosine kinase inhibitors (TKIs), from imatinib to
newer agents such as nilotinib, has led to progressively lower levels of disease burden in …

Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …

This study describes the analytical performance of the QuantideX qPCR BCR-ABL IS Kit, the
first Food and Drug Administration–cleared assay designed to monitor breakpoint cluster …

Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph)
translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine …